Introduction
============

Cardiovascular diseases (CVDs) are among the leading cause of death globally. According to the World Health Organization (WHO), 17.7 million people died from CVDs in 2015, representing 31% of all global deaths,[@b1-vhrm-14-165] a number that is expected to grow.[@b2-vhrm-14-165],[@b3-vhrm-14-165] Populations most affected are from low- and middle-income countries like Bangladesh, where 80% of these deaths occur.[@b3-vhrm-14-165] In these countries, the projected cumulative economic losses from all noncommunicable diseases will be \$7.28 trillion from 2011 to 2025 and CVD will account for nearly half of this projected loss.[@b4-vhrm-14-165] Against this backdrop, CVD is considered as a major public health concern worldwide.

Bangladesh has experienced a significant increase in the prevalence of noncommunicable chronic diseases and associated mortality in the last few decades.[@b5-vhrm-14-165],[@b6-vhrm-14-165] A rapid urbanization took place in Bangladesh in the past few decades due to its fast economic growth, and recently, it has emerged as a developing country.[@b5-vhrm-14-165],[@b7-vhrm-14-165] The results of this growth and urbanization increase the concern that a further rise in the chronic disease burden may be seen due to habituation of a sedentary life style (changing food habits including growing access to and demand for processed food, inconsistent meal times and reduced physical activity).[@b8-vhrm-14-165]

Population-based surveillance system to track noncommunicable chronic disease is currently absent in Bangladesh. In addition, it is hard to find accurate information on the prevalence of diseases in Bangladesh due to lack of national population-based surveys or central administrative health data. A limited number of studies have been undertaken on the prevalence of CVD in the Bangladeshi population,[@b9-vhrm-14-165]--[@b12-vhrm-14-165] of which only two discussed the burden of CVD.[@b13-vhrm-14-165],[@b14-vhrm-14-165] There is also little research that synthesizes existing studies on the prevalence of CVD through proper systematic review and that assesses overall prevalence and heterogeneity through meta-analysis. The lack of information on the prevalence of CVD restricts health professionals and policy makers from realizing the magnitude of the problem in Bangladesh. To plan and execute preventive strategy for CVD, detailed information about the prevalence of CVD can be very effective and play a vital role. To address this gap, this systematic review and meta-analysis was conducted on data published in the scientific literature to gain a better understanding of the prevalence of CVD in Bangladeshi adult.

Materials and methods
=====================

Data sources and search strategy
--------------------------------

Electronic databases such as MEDLINE, Embase and PubMed (from inception to April 13, 2017) were searched systematically to identify studies presenting information on the prevalence of CVD among the Bangladeshi adult population. To collect information about other possible studies, the reference lists of all pertinent publications were also searched. We only included studies published in English. The search strategy was based on three key components: CVD, prevalence and Bangladesh. The detailed search strategy is presented in [Table 1](#t1-vhrm-14-165){ref-type="table"}. In this review, we have used the term "cardiovascular disease (CVD)" according to the WHO[@b1-vhrm-14-165] definition, where CVD includes the following: 1) coronary heart disease (CHD); 2) cerebrovascular disease; 3) peripheral arterial disease; 4) rheumatic heart disease; 5) congenital heart disease; 6) deep vein thrombosis; 7) pulmonary embolism; 8) heart attack and 9) stroke. We defined prevalence as the proportion of a population who have (or had) CVD in a given time period. The summary statistics from the individual studies were prevalence, defined as the number of people in the sample with CVD divided by the total number of people in the sample. Overall prevalence of CVD was defined as the prevalence of all types of CVD together. We defined prevalence of the specific type of CVD (eg, CHD, stroke, congenital heart disease, etc.) separately rather than the combined prevalence.

Study selection
---------------

Potential eligible articles were identified by two reviewers independently using a two-step process. First, titles and abstracts were screened. Abstracts were retained if they were from an original study (no review articles) and presented data on the prevalence of CVD in Bangladesh. At this stage, an abstract was retained when either of the reviewers agreed that it should be or when there was confusion as to qualification based on title and abstract alone. Selected abstracts were screened thereafter on the basis of a full-text review. We tried to deliver a comprehensive systematic review of the topic by considering extensive inclusion criteria. No restriction was imposed on study type (eg, cohort study, cross-sectional study), geographical region (eg, urban, rural) or age ranges. A study was included if the prevalence of CVD was reported in the general adult Bangladeshi population but excluded if the prevalence was reported on individuals with specific diseases (eg, diabetes, hypertension). We excluded non-human studies, studies involving children and other biomedical studies that did not present prevalence of CVD. We measured agreement between reviewers. Any issue related to disagreement between reviewers was solved through consensus.

Data extraction
---------------

The following information was extracted from the included studies: author and publication year, age range of the study participants, gender and number of study participants, area (urban/rural) in which the study was carried out, sample selection procedure, study design, main outcome of the study, criteria used to diagnose CVD and the prevalence of CVD. Data were extracted using a standardized form by two reviewers independently. Each reviewer assessed study quality according to the Joanna Briggs Institute's guide to conducting prevalence and incidence reviews,[@b15-vhrm-14-165],[@b16-vhrm-14-165] and these data were extracted from each study for quality assessment purposes: was the sample representative of the target population; were study participants recruited properly; was the sample size sufficient; were the study subjects and setting described elaborately; was the data analysis carried out with adequate coverage of the identified sample; were objective, standard criteria used for measurement of the condition; was the condition measured precisely and were all the important confounding factors/subgroups/differences identified and considered.

Data analysis
-------------

Studies were grouped on the basis of the type of CVD according to outcome and gender and geographical location of the study participants. Random-effects meta-analysis was used to obtain the weighted pooled prevalence with 95% CIs for studies. A random-effects meta-analysis model assumes that the observed estimates of prevalence (treatment effect) can vary across studies because of both the real differences (heterogeneity) and sampling variability (chance) in the prevalence in each study as opposed to a fixed-effect meta-analysis model where the assumption is that there is no between-study heterogeneity in the true prevalence.[@b17-vhrm-14-165]

Heterogeneity was determined using Cochran's Q test and the *I*^2^ statistic and was evaluated using meta-regression and stratified analyses according to the type of CVD and gender and geographical location of the study participants. Cochran's Q test is the classical measure of heterogeneity measured as the weighted sum of squared differences between individual study prevalence and the pooled prevalence across studies, with the weights being those used in the pooling method. The distribution of Q-statistic is chi square with *m* (number of studies) minus one degree of freedom.[@b18-vhrm-14-165],[@b19-vhrm-14-165] *I*^2^ measures the percentage of variability in prevalence estimates that is due to between-study heterogeneity rather than chance.[@b18-vhrm-14-165],[@b19-vhrm-14-165] Small-study effects were judged applying a funnel plot and Egger's test. Inter-rater reliability was calculated. Stata version 13.1 (StataCorp LP, College Station, TX, USA) was used to perform statistical analysis using the following commands: metaprop, metareg, metabias, metatrim and metafunnel.

Results
=======

A total of 743 studies on the prevalence of CVD in Bangladesh were identified from our electronic search, and a further 12 potentially relevant papers were revealed in our search of the grey literature. After excluding duplicates and reviewing titles and abstracts, 27 articles were left for full-text screening. Irrelevance with study objective was the main reason for exclusion. Of the 27 articles screened, 14 were removed for the following reasons: two were conducted on individuals with diseases, eight were not an original article (seven review papers and one editorial), one consisted of subjects from overall South Asia, one was carried out on children and two were duplicate studies. Therefore, 13 studies were ultimately included for this systematic review. Agreement (94.23%) between reviewers on the primary articles eligible for inclusion was good. The article selection process is shown in [Figure 1](#f1-vhrm-14-165){ref-type="fig"}.

A summary outlining the characteristics of the included studies on the prevalence of CVD in Bangladeshi adult population is presented in [Table 2](#t2-vhrm-14-165){ref-type="table"}. Almost half of the studies were carried out in rural populations (six out of 13). Two studies were carried out on urban populations, three studies in both rural and urban populations and two studies in rural, suburban and urban populations. Different types of CVD were reported: six studies reported stroke, two ischemic heart disease (IHD), one CVD, two CHD, one congenital heart disease, two heart disease, one heart attack and one angina pectoris. Both genders were represented in all studies. Study design was cross-sectional in nine studies, prospective observational in one study and multistage prospective in one study. One study was conducted in two phases, with the first phase being over a 10-year period, and one study did not report the study design. Samples were selected using a simple random sampling procedure in only three studies, and four studies did not report the sample selection procedure.

The studies included in the present systematic review comprised 129,740 subjects, 50.96% of whom were men and 49.04% women. The age of the participants was ≥20 years in most studies. Prevalence of CVD was recorded by all the studies and ranged from 0.062% to 77.7%. Only one study[@b10-vhrm-14-165] recorded age-adjusted prevalence of CVD. The rest of the studies recorded overall prevalence, gender-specific and geographical location-specific prevalence and prevalence of specific types of CVD.

The weighted pooled prevalence of CVD regardless of gender and geographical location of the study participants and the types of CVD reported was 5.0% (95% CI: 3%--9%). Severe heterogeneity was observed in the prevalence of CVD (*I*^2^=99.78%; Cochran's Q-statistic *p*\<0.001; [Figure 2](#f2-vhrm-14-165){ref-type="fig"}). Meta-regression failed to identify gender (male vs female, *p*=0.881) and geographical location (urban vs rural, *p*=0.094) of the study participants as a probable source of heterogeneity in the overall CVD prevalence. In addition, the joint test[@b29-vhrm-14-165] of CVD types after adjusting for gender (*p*=0.069) and after adjusting for geographical location (*p*=0.070) of the study participants did not show any evidence that the prevalence differed among the types of CVD reported in the studies.

Subgroup analysis based on the gender of study participants
-----------------------------------------------------------

Although initial overall tests for heterogeneity based on gender of the study participants were nonsignificant (*p*=0.881), gender differences existed in CVD prevalence due to differences in genetic and psychosocial risk factors in men and women.[@b30-vhrm-14-165]--[@b32-vhrm-14-165] As such, a subgroup analysis according to the gender of the study participants was performed to explore any possible differences in CVD prevalence ([Figure 3](#f3-vhrm-14-165){ref-type="fig"}). Weighted pooled prevalence of CVD was the same in both females (3% \[95% CI: 1%--7%\]) and males (3% \[95% CI: 1%--6%\]). A severe unexplained between-study heterogeneity (*I*^2^=99.73%; Cochran's Q-statistic *p*\<0.001; [Figure 3](#f3-vhrm-14-165){ref-type="fig"}) in the prevalence of CVD was observed when study participants were female only. Meta-regression failed to identify geographical location of the study participants (urban vs rural, *p*=0.321) or the CVD types (joint test, *p*=0.109) after adjusting for geographical location of the study participants as the source of heterogeneity. In addition, a severe unexplained between-study heterogeneity (*I*^2^=99.64%; Cochran's Q-statistic *p*\<0.001; [Figure 3](#f3-vhrm-14-165){ref-type="fig"}) in the prevalence of CVD was observed when study participants were male only. Meta-regression again failed to identify geographical location of the study participants (urban vs rural, *p*=0.311) or the CVD types (joint test, *p*=0.118088) after adjusting for geographical location of the study participants as the source of heterogeneity.

Subgroup analysis based on the geographical location of study participants
--------------------------------------------------------------------------

The prevalence of CVD and associated risk factors could vary substantially in urban and rural areas, particularly in developing countries like Bangladesh, due to differences in lifestyles, which was clearly evident from the study.[@b33-vhrm-14-165] Although initial overall tests for heterogeneity based on geographical location (urban vs rural, *p*=0.094) were non-significant, we carried out a subgroup analysis according to the geographical location of the study participants to explore any possible differences in CVD prevalence ([Figure 4](#f4-vhrm-14-165){ref-type="fig"}). Weighted pooled prevalence of CVD was higher in urban areas (8% \[95% CI: 3%--14%\]) compared to rural areas (2% \[95% CI: 1%--4%\]). A severe between-study heterogeneity (*I*^2^=99.87%; Cochran's Q-statistic *p*\<0.001; [Figure 4](#f4-vhrm-14-165){ref-type="fig"}) in the prevalence of CVD was observed when study participants were from urban areas only. Meta-regression failed to identify the gender of the study participants (male vs female, *p*=0.903) as the source of heterogeneity but did identify CVD types (joint test, *p*=0.028) after adjusting for gender of the study participants as the source of heterogeneity. In addition, a severe between-study heterogeneity (*I*^2^=98.12%; Cochran's Q-statistic *p*\<0.001; [Figure 4](#f4-vhrm-14-165){ref-type="fig"}) in the prevalence of CVD was observed when study participants were from rural areas only. Meta-regression again failed to identify the gender of the study participants (male vs female, *p*=0.776) as the source of heterogeneity but did identify CVD types (joint test, *p*=0.011) after adjusting for gender of the study participants as the source of heterogeneity.

Subgroup analysis based on the types of CVD
-------------------------------------------

It is very well known that the prevalence of CVD varies depending on the type of CVD considered in studies. Hence, the differences in the types of CVD included in the studies in the present analysis makes meaningful pooling of CVD prevalence difficult and could be a major source of heterogeneity. To further explore heterogeneity, we carried out a subgroup analysis by dividing the studies according to the type of CVD reported ([Figure 5](#f5-vhrm-14-165){ref-type="fig"}).

Our review identified 13 studies describing eight different types of CVD (stroke, IHD, heart disease, angina pectoris, congenital heart disease, CHD, heart attack and CVD) prevalence. Although our search, which was undertaken according to the WHO definition of CVD, included nine different types of CVD, some CVD types (eg, rheumatic heart disease) were not identified. Not finding any prevalence studies on rheumatic heart disease in the adult population was unexpected, despite the fact that a large proportion of Bangladeshi population suffers from malnutrition and lives in unhygienic conditions, both of which are related with the development of this disease. We then grouped available CVD types into five major CVD categories (stroke, CHD, heart disease, congenital heart disease and CVD) based on their clinical manifestation. We treated IHD, angina pectoris and heart attack as CHD while grouping, since IHD consists principally of CHD and angina pectoris and heart attack are the major clinical manifestations of CHD.[@b34-vhrm-14-165]

Among the studies that recorded the prevalence of stroke, weighted pooled prevalence of stroke was 1% (95% CI: 1%--2%) with unexplained significant severe heterogeneity between studies (*I*^2^=96.88%; Cochran Q-statistic *p*\<0.001; [Figure 5](#f5-vhrm-14-165){ref-type="fig"}). Meta-regression did not find gender (male vs female, *p*=0.644) and the geographical location (urban vs rural, *p*=0.689) of the study participants to be responsible for the heterogeneity between the studies in this subgroup.

In the studies that recorded the prevalence of CHD, weighted pooled prevalence of CHD was 4% (95% CI: 2%--6%) with unexplained significant severe heterogeneity between studies (*I*^2^=97.17%; Cochran Q-statistic *p*\<0.001; [Figure 5](#f5-vhrm-14-165){ref-type="fig"}). Meta-regression did not find the geographical location (urban vs rural, *p*=0.440) of the study participants to be responsible for the heterogeneity between the studies in this subgroup. Most of the studies reported overall prevalence of CHD rather than gender-specific prevalence, which restricted performing meta-regression based on gender in the CHD subgroup. Individually, the CVD types that comprised the CHD category had different prevalence. The weighted pooled prevalence of IHD was 2%, that of CHD was 4% and that of heart attack was 2%. Only one study reported 21% prevalence of angina pectoris.

Two studies described heart disease prevalence; however, the definition of heart disease was not clear in either study.[@b12-vhrm-14-165],[@b23-vhrm-14-165] Van Minh et al[@b12-vhrm-14-165] did not provide a definition of what they meant by heart disease. Malik[@b23-vhrm-14-165] also did not provide any formal definition of heart disease; however, he indicated the distribution of various conditions in individuals with heart disease, which included hypertension, rheumatic valvular disease, IHD, cardiac arrhythmia, congenital heart disease, cardiomyopathy and cor pulmonale. The weighted pooled prevalence of heart disease in these two studies was 21% (95% CI: 5%--43%) with unexplained significant high heterogeneity between studies (*I*^2^=99.87%; Cochran Q-statistic *p*\<0.001; [Figure 5](#f5-vhrm-14-165){ref-type="fig"}). Meta-regression did not find gender (male vs female, *p*=0.852) and the geographical location (urban vs rural, *p*=0.329) of the study participants to be responsible for the heterogeneity between the studies in the heart disease subgroup.

Weighted pooled prevalence of congenital heart disease was 5% (95% CI: 4%--5%). As only two studies reported prevalence of congenital heart disease, heterogeneity was not assessed. CVD was reported by only one study, with 1% (95% CI: 1%--2%) prevalence being observed.

Assessment of temporal change in CVD prevalence
-----------------------------------------------

To assess the temporal change in CVD prevalence, we performed meta-regression on CVD prevalence over the study year. Overall prevalence of CVD increased by 0.12% (*p*=0.71; [Figure 6A](#f6-vhrm-14-165){ref-type="fig"}) for every 1 year increase in study year, suggesting that the prevalence of CVD is on the rise. The increase in CVD prevalence over the study year was not similar in different CVD types ([Figure 6B](#f6-vhrm-14-165){ref-type="fig"}). The increase in CVD prevalence was higher for congenital heart disease compared to other CVD types. For stroke, the prevalence was quite stable over time, although the time span was short (2008--2015). For CVD, it was not possible to observe temporal change due to the availability of only one study.

Study quality assessment
------------------------

Study quality was evaluated using criteria set out in the Joanna Briggs Institute's guide to conducting prevalence and incidence reviews[@b15-vhrm-14-165],[@b16-vhrm-14-165] and is outlined in [Table 3](#t3-vhrm-14-165){ref-type="table"}. A set of eight criteria was used to evaluate study quality. The sample represented the target population in all studies. Study participants were enrolled appropriately in six (46%) studies. The sample size was sufficient in only one (8%) study. Study participants and setting were described elaborately in six (46%) studies. Data analysis was carried out with reasonable coverage of the identified sample in four (31%) studies. An objective, standard criterion was used to precisely measure the conditions in eight (62%) and seven (54%) studies considered as major confounding factors and subgroups.

Publication bias
----------------

The funnel plot indicated the presence of asymmetry and publication bias ([Figure 7](#f7-vhrm-14-165){ref-type="fig"}), and Egger's test (*p*=0.001) confirmed the existence of small-study effects, in which small-sized studies reported a higher prevalence of CVD. We applied a trim and fill method[@b35-vhrm-14-165],[@b36-vhrm-14-165] as a form of sensitivity analysis to see how bias in the pooled estimates could be reduced. We obtained an overall 0.4% adjusted pooled prevalence of CVD with the fixed--random-effects trim and fill model. According to Peters et al,[@b37-vhrm-14-165] a fixed--random-effects trim and fill model performs better (is least biased) than other trim and fill models in our context (large between-study heterogeneity and publication bias). According to this model, 16 studies were assumed to be missing, which was adjusted for in the fixed--random-effects trim and fill model. This resulted in what appeared to be a large difference in unadjusted and adjusted overall CVD prevalence estimates (5% vs 0.4%). Funnel plot asymmetry can be due to many reasons other than publication bias. We also do not know with any certainty that publication bias is the true cause of funnel plot asymmetry. As such, we remained cautious in interpreting this adjusted pooled prevalence estimate. This adjusted pooled estimate may not represent an accurate summary of the evidence base and can be misleading in reflecting true prevalence of CVD.

Discussion
==========

This systematic review and meta-analysis gives summary estimates for the prevalence of CVD in the Bangladeshi adult population. The findings of this review suggest that the weighted pooled prevalence of CVD is between 1% and 21% depending on the type of CVD reported by studies. The highest pooled prevalence (21%) was reported for heart disease, while the lowest pooled prevalence (1%) was reported for stroke. The observed overall pooled prevalence of CVD regardless of the type of CVD was 5% in Bangladesh. Differences in the prevalence in different types of CVD are mainly due to the nature of each CVD type. The observed weighted pooled prevalence of CHD and congenital heart disease was quite similar. There can be few reasons for the relatively low stroke prevalence. The short duration of stroke illness, its low incidence, the challenges associated with the diagnosis of stroke that are mainly due to the cost and availability of tests (eg, computed tomography \[CT\] scans and magnetic resonance imaging \[MRI\], which are expensive and not available in most rural areas) and low survival after an acute event (due to lack of proper treatment facilities, particularly in rural areas) can potentially be attributed to the low prevalence of stroke in Bangladesh. Conversely, a high prevalence of heart disease was observed. Although such a high prevalence of heart disease is based on only two studies, we could not identify potential causes for that. The definition of heart disease was absent in one study, while several conditions were considered in defining heart disease in the other study. Including such conditions in the definition of heart disease can potentially inflate its prevalence.

We saw mixed results when we compared our findings with reports from other regions. The crude prevalence of CHD in the urban and rural areas of neighboring India was reported to be from 1.04% to 13.21% and 1.60% to 7.43%, respectively.[@b38-vhrm-14-165] The same study reported an age-adjusted prevalence of stroke in urban and rural areas of India of 0.33%--0.42% and 0.08%--0.26% respectively.[@b38-vhrm-14-165] The overall prevalence of heart attack and stroke was reported to be 6.2% and 2.6%, respectively, in Pakistan.[@b39-vhrm-14-165] The prevalence of stroke was reported to be 1.04%,[@b40-vhrm-14-165] and age- and gender-standardized prevalence of IHD was reported to be 9.3% in Sri Lanka.[@b41-vhrm-14-165] Prevalence of CVD in Nepal was reported to be 5.7%[@b42-vhrm-14-165] and that of coronary artery disease was reported to be 5%.[@b43-vhrm-14-165] A population-based study of ethnic groups in Canada reported 10.7% prevalence of any CVD among South Asians, 2.4% prevalence of any CVD among Chinese and 5.4% prevalence of any CVD among Europeans.[@b44-vhrm-14-165] The same study reported 1% prevalence of stroke among South Asians, 2% prevalence of stroke among Chinese and 6% prevalence of stroke among Europeans.[@b44-vhrm-14-165]

This study demonstrated that the weighted pooled prevalence of overall CVD in the Bangladeshi population is higher in urban areas (8%) compared to rural areas (2%). However, no such difference was observed in terms of gender. The weighted pooled prevalence of overall CVD was the same and was observed to be 3% in both males and females. The underlying factors behind the increased prevalence of CVD in urban populations could be multifarious. The prevalence of CVD could depend on several factors, including lifestyle, diet, environmental factors, and other population-specific risk factors. In developing countries like Bangladesh, people who live in urban areas have a different lifestyle and dietary pattern than those who live in rural areas. Urban residents have a more sedentary lifestyle than rural residents, who are often involved with heavy physical activity, and this difference contributes significantly to CVD prevalence. Differences in food supply and consumption patterns in urban areas and limited food diversity in rural areas influence dietary patterns and thus the status of CVD prevalence. Furthermore, urban residents are exposed to different environmental conditions (eg, access to physical activity facilities, better transportation, lack of open spaces and exposure to air pollution) than those who reside in rural areas. In general, the prevalence of CVD in Bangladesh is on the rise. The underlying factors behind the increased prevalence of CVD in the Bangladeshi population could be many. However, a geographical change in disease patterns from communicable to noncommunicable diseases, a growing trend of urbanization and an attraction for following a Western lifestyle could influence such increased CVD prevalence.[@b45-vhrm-14-165],[@b46-vhrm-14-165]

Our findings suggest an increasing prevalence of CVD in Bangladesh. With the rapid urbanization in the last 2 decades, substantial socioeconomic and demographic changes have occurred in Bangladesh, which are likely to increase CVD prevalence and the morbidity and mortality associated with it in the future. It is believed that such urbanization is associated with several risk factors for CVD, such as less physical activity, an unhealthy diet, increased stress and anxiety and changes in behavioral factors, all of which contribute to an increasing CVD prevalence. CVD and its risk factors are a major cause of premature death and chronic disability in Bangladesh and account for 13.4% of disability-adjusted life years (DALYs) lost there.[@b47-vhrm-14-165] This rising burden of CVD demonstrates the importance of increased effort in the prevention and treatment of it in Bangladesh.

We noticed high between-study heterogeneity among the studies. In an attempt to explore possible sources of heterogeneity, we carried out a subgroup analysis according to study area (urban/rural), gender (male/female) and CVD type (stroke/CHD/heart disease/congenital heart disease). Heterogeneity was still noticed within the subgroups, and often, we failed to locate the source of heterogeneity within the subgroups.

We detected evidence of small-study effect (*p*=0.001), in which small-sized studies reported a higher prevalence of CVD. In addition, the asymmetry on the funnel plot clearly demonstrated the presence of publication bias. Study quality evaluation indicates that almost all the studies failed to meet the criteria of "adequate sample size" for their studies. Also in many studies, data analysis was performed without adequate coverage of the identified sample, a point to be noted.

The biggest strength of the present study is the comprehensiveness of the process, which included a search of three different databases, explicit inclusion/exclusion criteria, and a wide-ranging use of reference lists. Thus, it is very unlikely that any pertinent studies have been missed. Nevertheless, there are several limitations to our study. We only considered papers published in English and failed to consider very local journals that are not available through the major academic databases. Most of the studies identified in our review and included in the meta-analysis addressed very selected populations. In addition, the existence of publication bias in the selected studies may impair validity of pooling CVD prevalence estimates. These limitations may generate possible sampling bias and could potentially restrict the generalizability of our study results to the entire Bangladeshi population. The methodology used to define CVD conditions was also heterogeneous and not standard in most studies. Additionally, lack of uniform definitions of CVD, variance in the age groups included and the settings in the studies included in this review could result in restrictions in comparability.

Conclusion
==========

We believe our review is the first of its kind that systematically assessed the scientific literature on the prevalence of CVD in Bangladeshi adults and has attempted to provide a comprehensive report on study variability in the reported prevalence. According to our review, despite differences in CVD type, gender, age and geographical area of the participants studied, the prevalence of CVD is high, particularly in urban areas, and is rising in Bangladesh, and immediate action from both a clinical and a public health standpoint is recommended. Many of the studies identified in the present systematic review consist of datasets that are small and specific to the particular settings (eg, hospital patients or employees of an institution) or regions and indicate a lack of nationally representative data on the prevalence of CVD in Bangladesh. Well-designed, population--based, nationally representative surveys focusing on CVD and its associated risk factors are crucial to identify the severity of CVD prevalence in Bangladesh, to implement preventive strategies to alleviate further increase in the prevalence and to reduce the morbidity and mortality associated with CVD. It is also crucial to examine potential risk factors that need to be addressed, especially those related to lifestyle. Furthermore, it is also necessary to increase public awareness of the high prevalence of CVD and its associated risk factors including education programs on diet and healthier lifestyles. A proper understanding and information of these factors may be helpful in tracking CVD and could play a part in designing prevention strategies to confront this issue.
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Search strategy used in different databases

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  MEDLINE                                                                  PubMed                                                                                                                                                                                                                                                                                                   Embase
  ------------------------------------------------------------------------ -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------
  1\. exp Coronary Disease/\                                               Search ((Prevalence) AND Bangladesh) AND ((((((((((coronary heart disease) OR cerebrovascular disease) OR peripheral arterial disease) OR rheumatic heart disease) OR congenital heart disease) OR deep vein thrombosis) OR pulmonary embolism) OR cardiovascular disease) OR Heart attack) OR stroke)   1\. exp ischemic heart disease/\
  2. Coronary heart disease.mp.\                                                                                                                                                                                                                                                                                                                                                    2. Coronary heart disease.mp.\
  3. exp Cerebrovascular Disorders/\                                                                                                                                                                                                                                                                                                                                                3. exp cerebrovascular disease/\
  4. Cerebrovascular disease.mp.\                                                                                                                                                                                                                                                                                                                                                   4. exp peripheral occlusive artery disease/\
  5. exp Peripheral Arterial Disease/\                                                                                                                                                                                                                                                                                                                                              5. exp rheumatic heart disease/\
  6. exp Rheumatic Heart Disease/\                                                                                                                                                                                                                                                                                                                                                  6. exp congenital heart disease/\
  7. Congenital heart disease.mp.\                                                                                                                                                                                                                                                                                                                                                  7. exp deep vein thrombosis/\
  8. exp Venous Thrombosis/\                                                                                                                                                                                                                                                                                                                                                        8. exp lung embolism/\
  9. Deep vein thrombosis.mp.\                                                                                                                                                                                                                                                                                                                                                      9. exp cardiovascular disease/\
  10. exp Pulmonary Embolism/\                                                                                                                                                                                                                                                                                                                                                      10. exp heart infarction/\
  11. exp Cardiovascular Diseases/\                                                                                                                                                                                                                                                                                                                                                 11. exp cerebrovascular accident/\
  12. exp Myocardial Infarction/\                                                                                                                                                                                                                                                                                                                                                   12. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11\
  13. exp Stroke/\                                                                                                                                                                                                                                                                                                                                                                  13. exp prevalence/\
  14. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13\                                                                                                                                                                                                                                                                                                            14. exp Bangladesh/\
  15. exp Prevalence/\                                                                                                                                                                                                                                                                                                                                                              15. 12 and 13 and 14
  16. exp Bangladesh/\                                                                                                                                                                                                                                                                                                                                                              
  17. 14 and 15 and 16                                                                                                                                                                                                                                                                                                                                                              

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Characteristics of the studies that evaluated the prevalence of CVD in the Bangladeshi population

  Study                                                                         Publication year   Age range                                                           Gender   Sample size                                         Studyarea                    Sampling method                                                                                           Study design                                    Main outcome                   Criteria for diagnosis of CVD                                          Prevalence of CVD (%)
  ----------------------------------------------------------------------------- ------------------ ------------------------------------------------------------------- -------- --------------------------------------------------- ---------------------------- --------------------------------------------------------------------------------------------------------- ----------------------------------------------- ------------------------------ ---------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Mohammad et al[@b20-vhrm-14-165]                                              2011               ≥40 years                                                           Both     15,627                                              Urban, Sub-urban and Rural   Area by stratified random sampling, village/ward by random sampling, and households by first-come basis   Cross-sectional                                 Stroke                         A team of senior neurologist by full examination                       Overall=0.3, male=0.34, female=0.24, urban=0.31, suburban=0.231 and rural=0.327
  Ahmed et al[@b21-vhrm-14-165],[a](#tfn1-vhrm-14-165){ref-type="table-fn"}     2007               ≥50 years                                                           Both     226                                                 Rural                        Purposive selection                                                                                       Cross-sectional                                 IHD                            ECG tracing                                                            2.70
  Van Minh et al[@b12-vhrm-14-165]                                              2008               25--64 years                                                        Both     8,096 (total): 4,023 (H), 2,000 (W) and 2,073 (M)   Both                         Random sampling                                                                                           Cross-sectional                                 Stroke and heart disease       Self-reported                                                          In H: stroke: male=2.0 and female=1.5; heart disease: male=6.4 and female=7.8; in W: stroke: male=0.5 and female=0.7; heart disease: male=66.3 and female=77.7; in M: stroke: male=1.6 and female=1.8; heart disease: male=5.3 and female=10.7
  Zaman et al[@b22-vhrm-14-165]                                                 2015               ≥30 years                                                           Both     1,709                                               Rural                        All from the list of households                                                                           Cross-sectional                                 Stroke                         Confirmed by doctor's examination                                      Overall=0.94, male=1.45, female=0.45
  Zaman et al[@b22-vhrm-14-165]                                                 2015               ≥20 years                                                           Both     447                                                 Rural                        Simplerandom sampling                                                                                     Cross-sectional                                 IHD                            Presence of pathological Q wave on ECG or current medication for IHD   Overall=3.4, male=4.6 and female=2.7
  Malik[@b23-vhrm-14-165]                                                       1976               All ages                                                            Both     7,062                                               Both                         Not reported                                                                                              Cross-sectional                                 Heart disease                  X-ray of chest, ECG                                                    Heart disease=2.9, IHD=0.33, congenital heart disease=0.18
  Ahsan et al[@b24-vhrm-14-165],[b](#tfn2-vhrm-14-165){ref-type="table-fn"}     2009               44.8 years (mean age)                                               Both     163                                                 Urban                        Not reported                                                                                              Cross-sectional                                 Angina pectoris                ECG and echocardiography (2D and M mode)                               Angina pectoris=20.9
  Basri et al[@b25-vhrm-14-165]                                                 2013               Mean age 24.1 years (without stroke) and 50.5 years (with stroke)   Both     79,658                                              Urban, suburban and rural    Door to door in randomly selected wards/villages                                                          Two phases. First phase over a 10-year period   Stroke                         Not reported                                                           Overall=0.075, male=0.088, female=0.062, rural=0.085, suburban=0.081 and urban=0.071
  Rahman et all[@b26-vhrm-14-165],[c](#tfn3-vhrm-14-165){ref-type="table-fn"}   2012               ≤79 years                                                           Both     2,050                                               Urban                        All patients attended as outpatient or inpatient in hospital                                              Prospective observational                       Congenital heart               Echocardiography                                                       52.24
  Khanam et al[@b27-vhrm-14-165]                                                2011               ≥60 years                                                           Both     452                                                 Rural                        Random sampling                                                                                           Cross-sectional                                 Stroke                         Physical examinations Symptoms (dysarthria, dysphasia)                 Overall=0.9, male=0.5, female=1.2
  Sayeed et al[@b10-vhrm-14-165]                                                2010               ≥20 years                                                           Both     4,141                                               Rural                        Purposive selection                                                                                       Not reported                                    CHD                            History of angina, changes in ECG or diagnosed by a Cardiologist       Crude=1.8, age adjusted=1.85
  Zaman et al[@b9-vhrm-14-165]                                                  2007               ≥20 years                                                           Both     447                                                 Rural                        Not reported                                                                                              Cross-sectional                                 IHD                            Presence of pathological Q wave on ECG or current medication for IHD   Overall=3.4, male=4.6 and female=2.7
  Parr et al[@b11-vhrm-14-165]                                                  2011               \>25 years                                                          Both     8,591                                               Both                         Not reported                                                                                              Cross-sectional                                 CHD, heart attack and stroke   Self-reported                                                          CHD: urban=6.0, rural=4.7; heart attack: urban=1.3, rural=0.3; stroke: urban=1.8, rural=1.9
  Cravedi et al[@b28-vhrm-14-165]                                               2012               \>18 years                                                          Both     1,518                                               Rural                        Not reported                                                                                              Multistage prospective                          CVD                            By clinical staff                                                      1.32

**Notes:**

Extrapolated prevalence.

Study participants are university grants commission (UGC) employees.

Tertiary Level Hospital patients.

**Abbreviations:** CVD, cardiovascular disease; IHD, ischemic heart disease, ECG, electrocardiography; UGC, University Grants Commission; H, health system and infectious disease site; W, woman abuse tracking in clinic and hospital site; M, Matlab site; CHD, coronary heart disease.

###### 

Study quality assessment of studies that evaluated the prevalence of CVD in the Bangladeshi population

  Study                                     Was the sample representative of the target population?   Were study participants recruited in an appropriate way?   Was the sample size adequate?   Were the study subjects and setting described in detail?   Is the data analysis conducted with sufficient coverage of the identified sample?   Were objective, standard criteria used for measurement of the condition?   Was the condition measured reliably?   Are all the important confounding factors/subgroups/differences identified and accounted for?
  ----------------------------------------- --------------------------------------------------------- ---------------------------------------------------------- ------------------------------- ---------------------------------------------------------- ----------------------------------------------------------------------------------- -------------------------------------------------------------------------- -------------------------------------- -----------------------------------------------------------------------------------------------
  Mohammad et al (2011)[@b20-vhrm-14-165]   Yes                                                       Yes                                                        Not clear                       No                                                         Not clear                                                                           Yes                                                                        Yes                                    Yes
  Ahmed et al (2007)[@b21-vhrm-14-165]      Yes                                                       No                                                         Not clear                       Yes                                                        No                                                                                  Not clear                                                                  Yes                                    No
  Van Minh et al (2008)[@b12-vhrm-14-165]   Yes                                                       Yes                                                        Not clear                       Yes                                                        Not clear                                                                           Yes                                                                        Not clear                              Yes
  Zaman et al (2015)[@b22-vhrm-14-165]      Yes                                                       Yes                                                        Not clear                       No                                                         Yes                                                                                 Yes                                                                        Not clear                              No
  Zaman et al (2015)[@b22-vhrm-14-165]      Yes                                                       Yes                                                        Not clear                       Yes                                                        No                                                                                  Yes                                                                        Yes                                    Yes
  Malik (1976)[@b23-vhrm-14-165]            Yes                                                       No                                                         Not clear                       No                                                         Not clear                                                                           Not clear                                                                  Yes                                    Yes
  Ahsan et al (2009)[@b24-vhrm-14-165]      Yes                                                       Not clear                                                  Not clear                       No                                                         Yes                                                                                 Not clear                                                                  Yes                                    No
  Basri et al (2013)[@b25-vhrm-14-165]      Yes                                                       Not clear                                                  Not clear                       No                                                         Not clear                                                                           Yes                                                                        Not clear                              Yes
  Rahman et al (2012)[@b26-vhrm-14-165]     Yes                                                       Yes                                                        Not clear                       No                                                         Yes                                                                                 Yes                                                                        Yes                                    Yes
  Khanam et al (2011)[@b27-vhrm-14-165]     Yes                                                       Yes                                                        Not clear                       No                                                         No                                                                                  Yes                                                                        Yes                                    No
  Sayeed et al (2010)[@b10-vhrm-14-165]     Yes                                                       No                                                         Not clear                       Yes                                                        Not clear                                                                           Yes                                                                        Yes                                    Yes
  Zaman et al (2007)[@b9-vhrm-14-165]       Yes                                                       Yes                                                        Not clear                       Yes                                                        Not clear                                                                           Yes                                                                        Yes                                    Yes
  Parr et al (2011)[@b11-vhrm-14-165]       Yes                                                       Not clear                                                  Yes                             Yes                                                        Yes                                                                                 No                                                                         No                                     No
  Cravedi et al (2012)[@b28-vhrm-14-165]    Yes                                                       Not clear                                                  Not clear                       Yes                                                        Not clear                                                                           Not clear                                                                  Not clear                              No

**Abbreviation:** CVD, cardiovascular disease.
